STAT

•

Canal • 2 emisiuni

Știri

Știri

Actualizată bisăptămânal
Afaceri

Afaceri

Actualizată săptămânal

07.08.2025

364: Closing a zombie biotech, and Lilly's disappointing obesity readout

We bring on Natalie Holles, who was the CEO of Third Harmonic Bio, which recently decided to dissolve and return cash to shareholders. She walks us through why the company has decided to do this and her advice for other biotech CEOs. We also chat about a disappointing readout from Eli Lilly's key small molecule GLP-1 candidate, setbacks in Vertex's pain business, and the story behind Replimmune's recent FDA rejection.

07.08.2025

•

38 min.
19.11.2025

Fighting anti-vax bills in a red state — and winning

In the wake of the pandemic, North Dakota, like many states, suddenly saw a splintering of opinion around vaccines. “Not only was I concerned about the decline of vaccinations, but I was even more concerned about the fabric of communities,” Sandy Tibke, executive director of the Foundation for a Healthy North Dakota, said on the this week’s podcast. So she teamed up with Josh Gryniewicz of Odd Duck, a communications consultancy. Together, they crisscrossed North Dakota, hosting listening sessions on health-related topics that went well beyond vaccines. On this episode of the “First Opinion Podcast,” host Torie Bosch spoke with Sandy and Josh about their work and the lessons it offers others in public health.

19.11.2025

•

43 min.
27.03.2025

347: More HHS upheaval, 23andMe's bankruptcy, and AI for cancer survival

Adam, Elaine, and Allison discuss the Trump administration’s plan for huge job cuts and a restructuring of the country’s top health care agencies, the approval of the first drug to treat a devastating rare disease, and the bankruptcy of 23andMe. Then, they bring on the chief executive of startup Altis Labs to discuss new data from a study they conducted with AstraZeneca on an AI tool for cancer drug development.

27.03.2025

•

31 min.
29.05.2025

355: Moderna’s vaccine hit, the MAHA report, and an ASCO preview

The American Society of Clinical Oncology, or ASCO, kicks off its annual meeting this weekend in Chicago. We discuss what to watch at the meeting. Then, STAT’s infectious disease reporter Helen Branswell joins us to discuss RFK Jr.’s unprecedented move to strike Covid shot recommendations, and the cancellation of a $600 million contract with Moderna to develop, test and license vaccines for subtypes of flu. We also welcome chronic disease reporter Isa Cueto to discuss the key takeaways from a closely watched report from Kennedy’s Make America Healthy Again Commission.

29.05.2025

•

37 min.
20.03.2025

346: Zealand's obesity strategy and Immunovant's curious development plan

We chat about positive data from Immunovant's autoimmune drug candidate, a patient death linked to Sarepta's gene therapy, and dispatches from our STAT Breakthrough Summit East in New York. We also bring on Zealand Pharma CEO Adam Steensberg to talk about his company’s amylin-targeting obesity treatment, the partnership deal it recently signed with Roche, and his thoughts on the industry's intense focus on weight loss.

20.03.2025

•

43 min.
10.07.2025

360: NIH grant cuts, FDA transparency questions and biotech M&A

On this week’s episode of the Readout LOUD: A closer look at the NIH’s grant-cutting legal playbook, a not-so-transparent transparency push by the FDA commissioner, and another big biotech acquisition. Our colleague Anil Oza joins us to unravel a previously unseen memo he obtained from HHS that lays out the legal framework being used to justify the termination of NIH grants. The disclosure comes as legal fights over the legitimacy of these funding cuts are being challenged in multiple courts.

10.07.2025

•

25 min.
19.06.2025

358: FDA's gene therapy turmoil, and an alternative model for funding research

We discuss the tragic news that a second teenage boy with Duchenne muscular dystrophy died after taking Sarepta Therapeutics' gene therapy, raising renewed questions about the FDA's standards for approving drugs.We look at the continued turmoil within the FDA, including the forced dismissal of top gene therapy regulator Nicole Verdun, as well as the announcement of a controversial drug-review voucher program that seems to be steering the agency into politics.We also talk about a private equity firm's decision to fund a research lab at Harvard University, filling a void created by government spending cuts. And we look at the approval of a groundbreaking HIV prevention medicine from Gilead Sciences, as well as a recap of the big BIO convention this week and a preview of the upcoming American Diabetes Association meeting this weekend.

19.06.2025

•

30 min.
24.10.2024

328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions

Will an activist investor campaign against Pfizer lead to big changes at the struggling Pharma giant? Why are some experts questioning the regulatory standards used to approve gene therapies for Duchenne muscular dystrophy? What’s the difference between Novo Holdings and Novo Nordisk, and will it impact a $16 billion acquisition of Catalent? And what lies ahead for Robert F. Kennedy Jr. and the Make America Healthy Again movement?

24.10.2024

•

34 min.
12.12.2024

334: Pharma silence on RFK Jr. & parents trying to develop gene therapies for their children

Washington correspondent John Wilkerson joins to discuss why drugmakers have not lobbied against Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services, despite his repeated criticisms of the pharmaceutical industry. We also bring on our colleague Jason Mast to talk about the major hurdles in the field of gene therapy and how one father is trying to overcome them.

12.12.2024

•

35 min.
03.04.2025

348: Cuts, ousters and drama at the FDA

STAT’s FDA reporter Lizzy Lawrence joins to discuss her inside-the-agency reporting on how Robert F. Kennedy Jr. forced top FDA officials to resign at a time when newly sworn-in FDA Commissioner Makary is still figuring out how to get around the agency’s White Oak campus in suburban Maryland. Then: AstraZeneca presented positive mid-stage results this week on a PCSK9 pill that dramatically lowered cholesterol levels on top of traditional statins. R&D executive Sharon Barr joins to talk about why AstraZeneca views this experimental cardiovascular medicine as a key part of its growth strategy.

03.04.2025

•

31 min.

Voices from the frontiers of health and medicine

Site